<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24884/1561-6274-2017-21-6-54-59</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-313</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>ПРОТЕИНЫ МОЧИ И ФИБРОПЛАСТИЧЕСКИЕ ИЗМЕНЕНИЯ КОМПАРТМЕНТОВ ПОЧКИ ПРИ ИММУННЫХ ГЛОМЕРУЛОПАТИЯХ</article-title><trans-title-group xml:lang="en"><trans-title>URINE PROTEINS AND FIBROTIC LESIONS OF RENAL COMPARTMENTS IN IMMUNE GLOMERULOPATHIES</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богданова</surname><given-names>Е. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogdanova</surname><given-names>E. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Богданова Евдокия Олеговна - лаборатория биохимического гомеостаза.</p><p>197022, Росия, Санкт-Петербург, ул. Л. Толстого, д. 17, корп. 54, (812) 338-69-01</p></bio><bio xml:lang="en"><p>Bogdanova Evdokia - Laboratory of Biochemical Homeostasis.</p><p>197022, St. Petersburg, L. Tolstoy st., 17, build. 54, (812) 338-69-01</p></bio><email xlink:type="simple">evdokia.bogdanova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Галкина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Galkina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Галкина Ольга Владимировна - кандидат биологических наук, лаборатория биохимического гомеостаза.</p><p>197022, Санкт-Петербург, ул. Л. Толстого, д. 17, корп. 54,  (812) 338-69-01</p></bio><bio xml:lang="en"><p>Olga V. Galkina - PhD, Laboratory of Biochemical Homeostasis, head.</p></bio><email xlink:type="simple">ovgalkina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зубина</surname><given-names>И. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Zubina</surname><given-names>I. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зубина Ирина Михайловна - кандидат биологических наук, лаборатория биохимического гомеостаза.</p><p>197022, Санкт-Петербург, ул. Л. Толстого, д. 17, корп. 54,  (812) 338-69-01</p></bio><bio xml:lang="en"><p>Irina M. Zubina – PhD, Laboratory of Biochemical Homeostasis.</p></bio><email xlink:type="simple">zubina@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Добронравов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dobronravov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Добронравов Владимир Александрович - доктор медицинских наук, профессор, заместитель директора.</p><p>197022, Санкт-Петербург, ул. Л. Толстого, д. 17, корп. 54,  (812) 338-69-01</p></bio><bio xml:lang="en"><p>Vladimir A. Dobronravov -  MD, PhD, DSci, Prof., Vice Director.</p><p>197022, St. Petersburg, L. Tolstoy st., 17, build. 54, (812) 338-69-01</p></bio><email xlink:type="simple">dobronravov@nephrolog.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский  институт нефрологии,  Научно-клинический исследовательский  центр, Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Nephrology, Scientific and  Clinical Research Center, Pavlov First Saint-Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>28</day><month>11</month><year>2017</year></pub-date><volume>21</volume><issue>6</issue><fpage>54</fpage><lpage>59</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Богданова Е.О., Галкина О.В., Зубина И.М., Добронравов В.А., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Богданова Е.О., Галкина О.В., Зубина И.М., Добронравов В.А.</copyright-holder><copyright-holder xml:lang="en">Bogdanova E.O., Galkina O.V., Zubina I.M., Dobronravov V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/313">https://journal.nephrolog.ru/jour/article/view/313</self-uri><abstract><p>Количественное определение типов  экскретируемых с мочой белков при существенной протеинурии может быть полезным для оценки выраженности морфологических изменений, ответа на лечение и прогноз.</p><p>Целью исследования являлся анализ взаимосвязи мочевой экскреции высокои низкомолекулярных белков с выраженностью фибропластических изменений клубочков, канальцев, интерстиция и сосудов.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы.  В исследование были  включены 97  пациентов с  первичными иммунными гломерулопатиями: мембранозной  нефропатией  (n=22), болезнью минимальных изменений (n =13),  фокально-сегментарным гломерулосклерозом (n =30),  IgA нефропатией (n =32)  с выполненной биопсией почек. Измерения общего белка, иммуноглобулина G (IgG), трансферрина (Trf), α1микроглобулина (α1-МГ),  β2-микроглобулина (β2-МГ) проводили нефелометрическим методом в образцах утренней мочи,  результаты стандартизировали по концентрации креатинина (Cr) в моче.</p></sec><sec><title>Результаты</title><p>Результаты.  Выявлена корреляция протеинурии и профиля исследуемых белков – β2-МГ (r=0,24, р=0,025), α1-МГ (r=0,38, р&lt;0,001), Trf (r=0,78, р&lt;0,001), IgG (r=0,67, р&lt;0,001), а также  корреляция между высоко(r=0,82, р&lt;0,001) и низкомолекулярными (r=0,30, p=0,004) белками. Экскреция низкомолекулярных белков (β2-МГ,  α1-МГ)  коррелировала с глобальным склерозом  клубочков (r=0,28, р=0,010 и r=0,21, р=0,049 соответственно), связь общей протеинурии и экскреции высокомолекулярных белков с фибропластическими гломерулярными изменениями отсутствовала. Выраженность тубулоинтерстициального повреждения была  ассоциирована только с экскрецией β2-микроглобулина (p&lt;0,020).</p></sec><sec><title>Заключение</title><p>Заключение. β2-МГ может рассматриваться как кандидатный интегральный биомаркер, указывающий на выраженность фибропластических изменений клубочков, тубулоинтерстиция и сосудов.</p></sec></abstract><trans-abstract xml:lang="en"><p>The quantification of specific urinary  proteins in high-grade proteinuria can  be  of importance for the  evaluation of mophrological lesions, response to therapy and  prognosis.</p><p>The aim of our study was to analyze whether the urinary  excretion of high and  low molecular proteins associated with the  degree of glomerular, tubulointerstitial and  vascular fibrosis.</p><sec><title>Patients and methods</title><p>Patients and methods. The study included 97 patients with biopsy proven primary immune glomerulopathies: membranous nephropathy (n =22), minimal change disease (n=13), focal segmental glomerulosclerosis (n =30), IgA nephropathy (n=32). Measurements of total  protein, immunoglobulin G (IgG),  transferrin (Trf), α1-microglobulin (α1-МG), β2-microglobulin (β2-MG)  were performed by nephelometric method in morning urine samples. The results were standardized for urine creatinine (Cr) concentration.</p></sec><sec><title>Results</title><p>Results. There were a correlation between proteinuria and  specific proteins: β2-MG (r=0.24, р=0.025), α1-МG (r=0.38, р&lt;0.001), Trf (r=0.78, р&lt;0.001), IgG (r=0.67, р&lt;0.001), as well as the  positive correlation between high and  low molecular proteins. Low molecular proteins (β2-МG,  α1-МG)  correlated with global  glomerular sclerosis (r=0.28, р=0.010 and  r=0.21, р=0.049 respectively) while levels of proteinuria and high molecular weight proteins did not. Urinary excretion β2-microglobulin was also significantly higher in patients with moderate-to-severe tubulointerstitial and vascular fibrotic lesions.</p></sec><sec><title>Conclusion</title><p>Conclusion. β2-microglobulin was suggested to be candidate integrative biomarker of renal  fibrosis in primary glomerulopathies.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>иммунные гломерулопатии</kwd><kwd>протеинурия</kwd><kwd>белки мочи</kwd><kwd>α1-микроглобулин</kwd><kwd>β2-микроглобулин</kwd><kwd>иммуноглобулин G</kwd><kwd>трансферрин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>immune glomerulopathies</kwd><kwd>proteinuria</kwd><kwd>urinary  proteins</kwd><kwd>α1-microglobulin</kwd><kwd>β2-microglobulin</kwd><kwd>immunoglobulin G</kwd><kwd>transferrin</kwd><kwd>fibrosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">SantucciL, BruschiM, CandianoGetal. Urine Proteome Biomarkers in Kidney Diseases. Limits, Perspectives, and First Focus on Normal Urine. Biomark Insights 2016; 11: 41–48</mixed-citation><mixed-citation xml:lang="en">SantucciL, BruschiM, CandianoGetal. Urine Proteome Biomarkers in Kidney Diseases. Limits, Perspectives, and First Focus on Normal Urine. Biomark Insights 2016; 11: 41–48</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Weissinger EM, Wittke S, Kaiser T et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. KidneyInt 2004; 65(6): 2426–2434</mixed-citation><mixed-citation xml:lang="en">Weissinger EM, Wittke S, Kaiser T et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. KidneyInt 2004; 65(6): 2426–2434</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Пролетов ЯЮ, Саганова ЕС, Галкина ОВ и др. Роль некоторых биомаркеров в оценке характера хронического повреждения почек у пациентов с первичными гломерулопатиями. Нефрология 2013;1:60 – 69 [ProletovYAYU, SaganovaES, GalkinaOVidr. Rol’ nekotoryhbiomarkerovvocenkeharakterahronicheskogopovrezhdeniyapochekupacientovspervichnymiglomerulopatiyami. Nefrologiya 2013; 1: 60 – 69]</mixed-citation><mixed-citation xml:lang="en">Пролетов ЯЮ, Саганова ЕС, Галкина ОВ и др. Роль некоторых биомаркеров в оценке характера хронического повреждения почек у пациентов с первичными гломерулопатиями. Нефрология 2013;1:60 – 69 [ProletovYAYU, SaganovaES, GalkinaOVidr. Rol’ nekotoryhbiomarkerovvocenkeharakterahronicheskogopovrezhdeniyapochekupacientovspervichnymiglomerulopatiyami. Nefrologiya 2013; 1: 60 – 69]</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fiseha T, Tamir Z. Urinary markers of Tubular Injury in Early Diabetic Nephropathy. Int J Nephrol 2016; 2016: 4647685. doi: 10.1155/2016/4647685</mixed-citation><mixed-citation xml:lang="en">Fiseha T, Tamir Z. Urinary markers of Tubular Injury in Early Diabetic Nephropathy. Int J Nephrol 2016; 2016: 4647685. doi: 10.1155/2016/4647685</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150(9): 604–612</mixed-citation><mixed-citation xml:lang="en">Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150(9): 604–612</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Du Buf-Vereijken PW, Wetzels JF. Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency. Nephrol Dial Transplant 2006; 21(2): 389–396 doi 10.1093/ndt/gfi219</mixed-citation><mixed-citation xml:lang="en">Du Buf-Vereijken PW, Wetzels JF. Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency. Nephrol Dial Transplant 2006; 21(2): 389–396 doi 10.1093/ndt/gfi219</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Shin JR, Kim SM, Yoo JS et al. Urinary excretion of β2microglobulin as a prognostic marker in immunoglobulin A nephropathy. Nephropathy Korean J Intern Med 2014; 29(3): 334-340. doi: 10.3904/kjim.2014.29.3.334</mixed-citation><mixed-citation xml:lang="en">Shin JR, Kim SM, Yoo JS et al. Urinary excretion of β2microglobulin as a prognostic marker in immunoglobulin A nephropathy. Nephropathy Korean J Intern Med 2014; 29(3): 334-340. doi: 10.3904/kjim.2014.29.3.334</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Branten AJW, Du Buf-Vereijken PW, Klasen IS et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005; 16(1): 169–174 doi: 10.1681/ASN.2004040287</mixed-citation><mixed-citation xml:lang="en">Branten AJW, Du Buf-Vereijken PW, Klasen IS et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005; 16(1): 169–174 doi: 10.1681/ASN.2004040287</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gluhovschi C, Gluhovschi G, Christos C et al. Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. Frontiers in Medicine 2017; 4 (73): doi.org/10.3389/fmed.2017.000</mixed-citation><mixed-citation xml:lang="en">Gluhovschi C, Gluhovschi G, Christos C et al. Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. Frontiers in Medicine 2017; 4 (73): doi.org/10.3389/fmed.2017.000</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Christensen EI, Birn H, Storm T et al. Endocytic receptors in the renal proximal tubule. Physiology (Bethesda) 2012; 27: 223–236:doi:10.1152/physiol.00022.2012</mixed-citation><mixed-citation xml:lang="en">Christensen EI, Birn H, Storm T et al. Endocytic receptors in the renal proximal tubule. Physiology (Bethesda) 2012; 27: 223–236:doi:10.1152/physiol.00022.2012</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nielsen R, Christensen EI, Birn H. Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int 2016; 89: 58–67; doi:10.1016/j.kint.2015.11.007</mixed-citation><mixed-citation xml:lang="en">Nielsen R, Christensen EI, Birn H. Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int 2016; 89: 58–67; doi:10.1016/j.kint.2015.11.007</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pallet N, Chauvet S, Chasse JF et al. Urinary Retinol Binding Protein Is a Marker of the Extent of Interstitial Kidney Fibrosis. PLoS One 2014; Jan 8;9(1):e84708. doi: 10.1371/journal.pone.0084708</mixed-citation><mixed-citation xml:lang="en">Pallet N, Chauvet S, Chasse JF et al. Urinary Retinol Binding Protein Is a Marker of the Extent of Interstitial Kidney Fibrosis. PLoS One 2014; Jan 8;9(1):e84708. doi: 10.1371/journal.pone.0084708</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Li L, Dong M, Wang XG. The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Chin Med J (Engl) 2016;129(4): 448-455</mixed-citation><mixed-citation xml:lang="en">Li L, Dong M, Wang XG. The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Chin Med J (Engl) 2016;129(4): 448-455</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Haymann JP, Levraud JP, Bouet S et al. Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol 2000; 11: 632–639</mixed-citation><mixed-citation xml:lang="en">Haymann JP, Levraud JP, Bouet S et al. Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol 2000; 11: 632–639</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Dobrinskikh E, Okamura K, Kopp JB et al. Human podocytes perform polarized, caveolae-dependent albumin endocytosis. Am J Physiol Renal Physiol 2014; 306: 941–951. doi:10.1152/ajprenal.00532.2013</mixed-citation><mixed-citation xml:lang="en">Dobrinskikh E, Okamura K, Kopp JB et al. Human podocytes perform polarized, caveolae-dependent albumin endocytosis. Am J Physiol Renal Physiol 2014; 306: 941–951. doi:10.1152/ajprenal.00532.2013</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kobayashi N, Suzuki Y, Tsuge T et al. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. American Journal of Physiology 2002; 282(2): 358-365. doi: 10.1152/ajprenal.0164.2001</mixed-citation><mixed-citation xml:lang="en">Kobayashi N, Suzuki Y, Tsuge T et al. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. American Journal of Physiology 2002; 282(2): 358-365. doi: 10.1152/ajprenal.0164.2001</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gan H, Feng S, Wu H et al. Neonatal Fc receptor stimulation induces ubiquitin c-terminal hydrolase-1 overexpression in podocytes through activation of p38 mitogen-activated protein kinase. Hum Pathol 2012; 43: 1482–1490. doi:10.1016/j.humpath.2011.10.025</mixed-citation><mixed-citation xml:lang="en">Gan H, Feng S, Wu H et al. Neonatal Fc receptor stimulation induces ubiquitin c-terminal hydrolase-1 overexpression in podocytes through activation of p38 mitogen-activated protein kinase. Hum Pathol 2012; 43: 1482–1490. doi:10.1016/j.humpath.2011.10.025</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kang S-W, Natarajan R, Shahed A et al. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen α5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J Am Soc Nephrol 2003; 14:3178–3187. doi:10.1097/01.ASN.0000099702.16315.DE</mixed-citation><mixed-citation xml:lang="en">Kang S-W, Natarajan R, Shahed A et al. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen α5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J Am Soc Nephrol 2003; 14:3178–3187. doi:10.1097/01.ASN.0000099702.16315.DE</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Koshikawa M, Mukoyama M, Mori K et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2690–2701. doi:10.1681/ASN.200412108</mixed-citation><mixed-citation xml:lang="en">Koshikawa M, Mukoyama M, Mori K et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2690–2701. doi:10.1681/ASN.200412108</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kavvadas P, Weis L, Abed AB et al. Renin inhibition reverses renal disease in transgenic mice by shifting the balance between profibrotic and antifibrotic agentsnovelty and significance. Hypertension 2013; 61: 901–907. doi:10.1161/HYPERTENSIONAHA.111.00639</mixed-citation><mixed-citation xml:lang="en">Kavvadas P, Weis L, Abed AB et al. Renin inhibition reverses renal disease in transgenic mice by shifting the balance between profibrotic and antifibrotic agentsnovelty and significance. Hypertension 2013; 61: 901–907. doi:10.1161/HYPERTENSIONAHA.111.00639</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kato Y, Mori K, Kasahara M et al. Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogen-activated protein kinase inhibition. SciRep 2017; 7:46624. doi:10.1038/srep4662</mixed-citation><mixed-citation xml:lang="en">Kato Y, Mori K, Kasahara M et al. Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogen-activated protein kinase inhibition. SciRep 2017; 7:46624. doi:10.1038/srep4662</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
